Vaccitech presents interim data from Phase 1b/2 study of VTP-200

Vaccitech will present topline data from the APOLLO clinical trial at the 35th Annual International Papillomavirus Conference, IPVC. The APOLLO trial is a fully enrolled Phase 1b/2 study of VTP-200 in women with low-grade cervical lesions associated with persistent human papillomavirus, HPV, infection. The data will be presented as a poster at IPVC in Washington, D.C. on Thursday, April 20, 2023 at 2 PM EDT, by Dr. Meg Marshall, Chief Medical Officer of Vaccitech. "The safety and immunogenicity data presented at IPVC shows the potential of VTP-200 in treating persistent high-risk HPV infections. Currently, women with persistent HPV infections have no treatment options until they develop high grade lesions," said Meg Marshall, CMO of Vaccitech. "We believe VTP-200 has the potential to address a serious unmet need and look forward to sharing the results of the final analysis, to include data on clearance of infection and cervical lesions, in 2024."